Daniel Vasella - 2009 CEO Pay

Daniel Vasella, Novartis CEO

Daniel Vasella - Novartis

Total Compensation: $17.8 million

Details: In his last year as Novartis' chairman and chief executive, Vasella received a base salary of $2.6 million in 2009, plus short-term incentives of about $99,000, long-term incentives totaling $1.6 million and benefits of about $385,000. He owned 2,924,114 shares in the company. After 14 years as Novartis' CEO, Vasella announced he was stepping down in January. He was replaced by Novartis pharma chief Joe Jimenez (photo).

Novartis News:
Vasella, Jimenez share the limelight
Novartis chief steps aside for Jimenez
New Novartis chief talks productivity
Novartis CEO goes on a 'decluttering' drive
Falling Novartis stock deflates bid for Alcon shares

Daniel Vasella - 2009 CEO Pay

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.